The FDA approved voracetamib for IDH-mutant gliomas following any surgery, including complete resection. This is significant because the pivotal INDIGO trial did not specifically study patients without residual tumor, broadening the drug's applicability in clinical practice beyond its original trial evidence.
Under current WHO guidelines, a histologically low-grade glioma can be reclassified as a high-grade (Grade 4) tumor based solely on molecular findings, such as a CDK2A/B deletion. This paradigm shift means molecular data is paramount, fundamentally changing patient prognosis and treatment strategy irrespective of microscopic appearance.
Advanced imaging techniques can provide clues about a glioma's molecular subtype before surgery. Specifically, a 'T2-FLAIR mismatch' finding on an MRI is highly indicative of an IDH-mutant astrocytoma, allowing clinicians to anticipate the tumor's molecular profile and plan treatment strategies earlier.
Clinicians must be cautious when interpreting genomic reports. A 'negative' result doesn't confirm the absence of a mutation; it only means the specific test, with its inherent limitations like an inability to detect copy number alterations, did not identify it. This distinction is critical for accurate diagnosis.
Different commercial and institutional molecular testing platforms can produce disparate results for the same tumor specimen. This variability in tests for markers like MGMT promoter methylation or 1p19q codeletion can lead to incorrect diagnoses and misguided treatment plans for glioma patients.
Historically, most clinical trials for diffuse midline glioma (DMG) were restricted to children. Recently, these trials have started including young adults, a significant shift that expands access to novel therapies for an adult patient population that previously had very limited experimental options.